Elevation Oncology (Elevation Oncology) Additional Paid-In Capital : $282.58 Mil(As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology Additional Paid-In Capital?

Elevation Oncology's quarterly additional paid-in capital increased from Sep. 2023 ($250.54 Mil) to Dec. 2023 ($250.83 Mil) and increased from Dec. 2023 ($250.83 Mil) to Mar. 2024 ($282.58 Mil).

Elevation Oncology's annual additional paid-in capital increased from Dec. 2021 ($195.88 Mil) to Dec. 2022 ($199.49 Mil) and increased from Dec. 2022 ($199.49 Mil) to Dec. 2023 ($250.83 Mil).

Elevation Oncology Additional Paid-In Capital Historical Data

The historical data trend for Elevation Oncology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevation Oncology Additional Paid-In Capital Chart

Elevation Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

0.01

0.07

195.88

199.49

250.83

Elevation Oncology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial												201.19	249.67	250.54	250.83	282.58

Elevation Oncology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Elevation Oncology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Elevation Oncology (Elevation Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106

Website

https://www.elevationoncology.com

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Executives

Tammy Furlong	officer: CHIEF FINANCIAL OFFICER	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen	officer: Chief Medical Officer	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff	other: Managing Member	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms	director, other: Managing Member	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin	director	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106